bioMérieux S.A./€BIM
1D1W1MYTD1Y5YMAX
Capital at risk
About bioMérieux S.A.
bioMérieux S.A. is a French company specialized in the field of in vitro diagnostics, operating within the healthcare industry. The company develops, manufactures, and markets diagnostic solutions that are primarily used for detecting disease-causing microorganisms. These solutions include a broad range of products, such as diagnostic tests for infectious diseases, cancer, and cardiovascular diseases, as well as industrial microbiological controls. Founded in 1963 by Alain Mérieux, bioMérieux is headquartered in Marcy-l'Étoile, near Lyon, France. The company has a global presence, serving clients around the world through a network of subsidiaries and distributors. Its competitive strength lies in its extensive product portfolio and commitment to research and development, enabling it to address evolving medical and industrial testing needs.
- Ticker
- €BIM
- Sector
- Health
- Primary listing
- PAR
- Employees
- 14,894
- Headquarters
- Marcy-l'Étoile, France
- Website
- www.biomerieux.com
bioMérieux S.A. Metrics
BasicAdvanced
€8.6B
18.97
€3.90
0.57
€0.98
1.32%
Price and volume
Market cap
€8.6B
Beta
0.57
52-week high
€116.30
52-week low
€64.00
Average daily volume
144K
Dividend rate
€0.98
Financial strength
Current ratio
2.302
Quick ratio
1.437
Long term debt to equity
0.044
Total debt to equity
0.098
Interest coverage (TTM)
49.70%
Profitability
EBITDA (TTM)
1,074.9
Gross margin (TTM)
56.13%
Net profit margin (TTM)
11.59%
Operating margin (TTM)
16.03%
Effective tax rate (TTM)
23.88%
Revenue per employee (TTM)
€270,000
Management effectiveness
Return on assets (TTM)
7.23%
Return on equity (TTM)
11.22%
Valuation
Price to earnings (TTM)
18.972
Price to revenue (TTM)
2.182
Price to book
2
Price to tangible book (TTM)
2.74
Price to free cash flow (TTM)
14.937
Free cash flow yield (TTM)
6.69%
Free cash flow per share (TTM)
4.954
Dividend yield (TTM)
1.32%
Forward dividend yield
1.32%
Growth
Revenue change (TTM)
-3.18%
Earnings per share change (TTM)
23.04%
3-year revenue growth (CAGR)
2.54%
10-year revenue growth (CAGR)
6.98%
3-year earnings per share growth (CAGR)
6.27%
10-year earnings per share growth (CAGR)
12.96%
3-year dividend per share growth (CAGR)
4.86%
10-year dividend per share growth (CAGR)
11.39%
Bulls say / Bears say
BioMérieux posted a 40.6% increase in H1 2026 net income to €226 million, underscoring improved profitability despite sales headwinds. (Reuters)
The company generated free cash flow of €299 million in H1 2026, a 75.8% year-on-year surge, strengthening its liquidity position. (Reuters)
SPOTFIRE® point-of-care diagnostics sales soared 36.6% in Q2 2026 to €34.3 million, demonstrating robust demand for its high-margin molecular testing platforms. (Reuters)
Organic sales growth was virtually flat at +0.2% in H1 2026, reflecting stagnating demand in core diagnostics segments. (Reuters)
BioMérieux reduced its medium-term 2027–28 organic revenue growth target to 3%–6%, down from approximately 7%, indicating tempered growth expectations. (Reuters)
First-half H1 2026 CEBIT declined 4.9% organically, pressured by a €35 million adverse currency effect, signaling margin headwinds. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2026.
Upcoming events
No upcoming events
Funds containing bioMérieux S.A.
AllUSDEURGBP
Fund name | Fund size | €BIM weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.42% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.42% |
iShares Healthcare Innovation£DRDR | £1B | 0.42% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 0.22% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 0.18% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.